2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 252-254
Treatment Considerations, Biological Therapies, Antibody Therapy, Adverse Events, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Infectious Diseases, Other Pathogens, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric
PAPER

465 8 weeks of dronabinol improves measures of social and emotional function in people with sickle cell disease and chronic pain compared to placebo.

Jordan Bellis, Lydia Monk2, Sarah McCuskee, MD, MPhil3, Charleen Jacobs-McFarlane, PhD, RN, ANP-BC4, Brittany McCrary, MS, AGPCNP-BC, RN5, Angela Liu, MD6, Jeffrey Glassberg, MD7, Susanna Curtis, MD, PhD8
1 Icahn School of Medicine at Mount Sinai, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, United States

Introduction: Chronic pain is the largest contributor to poor quality of life (QOL) in people living with sickle cell disease (SCD).  Many individuals with SCD report using cannabis to treat pain.  We hypothesized that dronabinol, an FDA approved capsule containing synthetic tetrahydrocannabinol (THC), the main active ingredient in cannabis, could be effective to treat pain and improve QOL in people with SCD and chronic pain.  We designed a placebo-controlled study with 8 weeks of individualized-dose dronabinol to evaluate its effect on safety, patient reported measures (PROs) of pain and QOL, and laboratory outcomes.

Methods: Subjects enrolled were adults (age>18) with SCD of any genotype and chronic pain, defined as pain on >50% of days for at least six months, on stable doses of pain and disease modifying medications for at least 3 months, at steady state, with urine toxicology negative for THC in the past 30 days, without history of psychosis or substance use disorder.

              Subjects were randomized 1:1 to dronabinol or placebo.  Doses started at 5mg twice daily (bid) and were titrated daily based on subject preference from minimum of 2.5 mg daily to maximum of 10 mg bid and then continued for 8 weeks.  All laboratory, pain and QOL measures (PROMIS: neuropathic and nociceptive pain quality, cognition, ASCQ-Me: pain impact, stiffness, sleep, emotional, and social impact) were taken at baseline and at 4 and 8 weeks on study.  Mass spectrometry for minor cannabinoids was measured to assess for abstinence from other cannabinoids during the study period. O-link inflammation panel was used to measure proteomics. Comparisons between dronabinol and placebo were made using the Mann-Whitney U test.

Results: 34 subjects were randomized between 10/2022 and 6/2026, with median age 35.4 ± 8.3 years old, 26/34 were female, 24 HbSS/HbSβ0, 10 HbSC/Hbβ+, 26/34 on hydroxyurea, 12/34 on crizanlizumab, and 12/34 on voxelotor (when it was available).  There was no difference in clinical characteristics between groups. Prior to randomization those assigned to dronabinol had superior baseline ratings for sleep, but otherwise there was no difference in baseline PROs between groups.

At 8 weeks, subjects on dronabinol had superior ratings for social (53.2 vs 46.8, p=0.0068) and emotional (54.1 vs 49.5, p=0.050) impact of disease. Ratings for pain measures and other QOL measures were all numerically superior for those on dronabinol but did not meet statistical significance (Pain Impact (48.7 vs 45.9, p=0.24), Stiffness (49.3 vs 43.6, p=0.18), Sleep (50.2 vs 43.1, p=0.10) Cognition (63.9 vs 53.6, p=0.20), Neuropathic Pain (44.7 vs 48.1, p=0.26), Nociceptive Pain 47.4 vs 54.4 p=0.08)). For all PROs, 50 is the median of the reference population and the SD is 10; higher numbers are superior except for neuropathic and nociceptive pain where lower numbers are superior.

There was no difference in complete blood count or measures of hemolysis (LDH, total bilirubin) between groups at 8 weeks.  However, subjects on dronabinol had reductions in markers of inflammation including markers of monocyte and mast cell activation MCP4 (p=0.02) and CCL23 (p=0.08) compared to placebo.

Eight subjects withdrew early but completed evaluations (dronabinol: 5 due to side effects, 1 due to pregnancy, 1 lost to follow up, placebo: 1 due to side effects). There was no significant difference in rates of SAEs between groups (0.83 vs 0.67, p=0.72), majority were VOE and none attributed to dronabinol. There was no difference in rates of experiencing at least one AE (0.50 vs 0.27, p=0.18) between groups. Mass spectrometry confirmed no subjects used cannabinoids other than dronabinol during the study.

Conclusions: In people with SCD and chronic pain, 8 weeks of dronabinol improved measures of social and emotional function.  Other measures of pain and QOL were improved but did not meet statistical significance. Other studies have suggested cannabinoids have a stronger impact on pain bothersomeness than pain severity which may be why larger improvements seen were in mood and daily functioning.  Subjects on dronabinol had reduced measures of mast cell activation which has also been demonstrated in murine models of SCD.  Mast cell activation plays a key role in neuro-inflammation so this suggests a possible mechanism of action. 

This study was single center, had a small sample size, and was 8 weeks which is not long enough to measure outcomes such as frequency of pain crises. 

Susanna Curtis, MD, PhD: Disc Medicine - Research Funding; Pfizer - Membership on a Board/Advisory Committee